Bioverativ Inc (BIVV) Now Covered by Royal Bank Of Canada
Research analysts at Royal Bank Of Canada assumed coverage on shares of Bioverativ Inc (NASDAQ:BIVV) in a report issued on Thursday, The Fly reports. The brokerage set a “sector perform” rating on the biotechnology company’s stock.
A number of other equities analysts also recently commented on BIVV. Credit Suisse Group upgraded Bioverativ from an “underperform” rating to a “neutral” rating and raised their price objective for the stock from $47.00 to $52.00 in a report on Wednesday, May 24th. Deutsche Bank AG initiated coverage on Bioverativ in a report on Friday, June 23rd. They issued a “hold” rating and a $65.00 price objective on the stock. Wedbush restated a “market perform” rating on shares of Bioverativ in a report on Wednesday, June 28th. William Blair initiated coverage on Bioverativ in a report on Wednesday, June 28th. They issued a “market perform” rating on the stock. Finally, Jefferies Group LLC restated a “buy” rating on shares of Bioverativ in a report on Friday, June 30th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $60.43.
Bioverativ (NASDAQ:BIVV) traded down 0.04% during trading on Thursday, reaching $56.44. The company’s stock had a trading volume of 493,877 shares. The company has a market capitalization of $6.11 billion and a P/E ratio of 13.42. Bioverativ has a 1-year low of $41.88 and a 1-year high of $57.82. The company’s 50-day moving average is $56.67 and its 200-day moving average is $54.23.
Bioverativ (NASDAQ:BIVV) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $0.88 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.17. The firm had revenue of $289.10 million during the quarter, compared to analysts’ expectations of $269.00 million. The business’s revenue for the quarter was up 37.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.59 earnings per share. Equities analysts anticipate that Bioverativ will post $2.92 EPS for the current year.
WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/14/bioverativ-inc-bivv-now-covered-by-royal-bank-of-canada.html.
In other Bioverativ news, Director Brian S. Posner acquired 1,000 shares of the stock in a transaction on Wednesday, August 9th. The stock was purchased at an average price of $59.19 per share, for a total transaction of $59,190.00. Following the purchase, the director now directly owns 6,693 shares in the company, valued at $396,158.67. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Louis J. Paglia acquired 2,000 shares of the stock in a transaction on Monday, August 7th. The shares were acquired at an average price of $59.70 per share, with a total value of $119,400.00. Following the purchase, the director now owns 5,056 shares in the company, valued at $301,843.20. The disclosure for this purchase can be found here.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.